Siga Technologies ( (SIGA) ) has released its Q1 earnings. Here is a breakdown of the information Siga Technologies presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the development of antiviral medicines for infectious diseases, with a focus on orthopoxviruses. The company is known for its flagship product, TPOXX, which is used to treat smallpox and other related diseases.
In its latest earnings report for the first quarter of 2025, SIGA Technologies highlighted a procurement order of $26 million for IV TPOXX from the U.S. Government and outstanding orders totaling $94 million for delivery to the U.S. Strategic National Stockpile. The company also noted a significant international sale of approximately $6 million, marking the start of anticipated substantial sales in the coming months.
The financial results for the quarter showed a decrease in total revenues to $7 million from $25.4 million in the same period last year, with product sales contributing $5.8 million. The company reported an operating loss of $2.3 million, compared to an operating income of $11.3 million in the previous year. Despite the decline in revenues, SIGA continues to secure significant government contracts and international approvals, including regulatory approval in Japan for its product TEPOXX.
Looking ahead, SIGA Technologies remains optimistic about its growth prospects, with plans to deliver $70 million of outstanding orders by the end of the third quarter of 2025 and the remainder in 2026. The company views these anticipated sales as a strong foundation for future expansion and continues to focus on its strategic initiatives to enhance its market presence.